Evidence-based "selection-prevention" model for AD: 100% biomarker response and 77.6% clinical improvement
Detailed Listing DescriptionMethodology & Clinical Dataset Our "Selection-Prevention" intervention utilizes a proprietary natural product formulation validated through a dual-track approach: preclinical mechanism research and extensive Real-World Evidence (RWE). We analyzed a longitudinal dataset of 407 patients treated for more than 6 months, achieving a 77.6% clinical response rate (average CGI-I score of 3.89) with zero reports of liver toxicity or serious adverse events across 1,000+ cases over 5 years. The core mechanism involves AMPK phosphorylation and inhibition of BACE1 expression, as published in the Journal of Alzheimer's Disease (2021).
Metrics, Validation & Next Steps The efficacy is further validated by blood-based biomarker tracking, where 100% of monitored patients showed a reduction in plasma Amyloid-beta (A\beta) levels. We recorded an average 20% reduction in A\beta, with high-risk ApoE4/4 carriers reaching a 22.3% reduction, significantly outperforming the declining trajectories of the NCAA (Normal Aging) cohort. Currently, we are finalizing a 15-patient cohort comparison study and preparing to launch a 30-subject clinical trial focused on the A/T/N (Amyloid, Tau, NfL) triple-marker system. Our next step is to secure a strategic partnership for global clinical scaling and high-impact publication (Target IF 5.0–10.0) to establish a new "Amyloid & Tau Dual Care" standard.
About chongnoi H&D
Chongnoi H&D operates a network of Korean medicine clinics, known as Chongnoi Oriental Medicine Clinic, which specialize in the treatment and prevention of dementia and Alzheimer's disease. The organization has developed a proprietary herbal medicine treatment called Cheongnoe-tang, which has been granted a patent for its efficacy in preventing, treating, or improving Alzheimer's disease. This treatment works by utilizing complex herbal extracts that have been scientifically studied for their ability to reduce amyloid-beta plaque accumulation and phosphorylated tau protein levels, which are critical biomarkers in Alzheimer's pathology. The clinical efficacy of these extracts has been documented in peer-reviewed international scientific journals.
By providing evidence-based, integrative treatment options, the clinic aims to support the cognitive health of an aging population. Their approach addresses the significant challenges faced by patients and their families, seeking to improve patient memory, cognitive function, and quality of life. The clinic's research is spearheaded by its affiliated biotechnology laboratory, which focuses on advancing scientific solutions for neurodegenerative conditions. Through a combination of clinical practice and ongoing research, Chongnoi H&D contributes to the management of cognitive health issues, supported by internal assessments and patient outcome monitoring.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.